"Gilead's Trodelvy Disappoints in Lung Cancer Trial, Stock Tumbles"
TL;DR
Gilead Sciences' antibody drug conjugate, Trodelvy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer in a recent study, raising questions about the effectiveness of this type of treatment in oncology. The disappointing results from the Evoke-01 study have implications for investors and oncologists, as antibody drug conjugates are considered a promising area in cancer treatment, combining an antibody with chemotherapy to target cancer cells.
Topics:businesshealthcare#antibody-drug-conjugates#gilead-sciences#healthcare#lung-cancer#oncology#trodelvy
- Gilead's Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs STAT
- Gilead Sinks After Lung Cancer Drug Fails to Improve Survival Yahoo Finance
- Gilead's stock tumbles as lung-cancer trial disappoints MarketWatch
- GILD Stock Tumbles 10% And Sacrifices A Breakout On Its Surprise Lung Cancer Treatment Flop Investor's Business Daily
- Gilead stock falls after lung cancer study results disappoint CNBC
Want the full story? Read the original reporting
Read on STAT